Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 Phase I/II Trial in Advanced Solid Tumors
ChiCTR2500099933Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CPO301 in advanced nonhematological malignancy, Pulmonary squamous cell carcinoma, non-small cell lung cancer (NSCLC) and 8 more (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
CPO301
03
Conditions
advanced nonhematological malignancyPulmonary squamous cell carcinomanon-small cell lung cancer (NSCLC)nasopharyngeal carcinoma (NPC)esophageal cancer
Beyond the preview
Go deeper on ChiCTR2500099933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099933.